Dupont Capital Management Corp Sells 9,579 Shares of Zoetis Inc. $ZTS

Key Points

• Dupont Capital Management Corp reduced its stake in Zoetis Inc. by 14.3%, selling 9,579 shares and holding 57,475 shares worth approximately $8.96 million as per the latest SEC filing.
• Zoetis reported a positive earnings quarter with an EPS of $1.76, exceeding analysts' estimates by $0.14, while revenues increased 4.2% year-over-year to $2.46 billion.
• The company announced a quarterly dividend of $0.50 per share, with a yield of 1.4%, and the payout is to be made on December 2nd to investors of record on October 31st.

Dupont Capital Management Corp reduced its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 14.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,475 shares of the company's stock after selling 9,579 shares during the period. Dupont Capital Management Corp's holdings in Zoetis were worth $8,963,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in ZTS. Brighton Jones LLC grew its stake in Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock worth $754,000 after acquiring an additional 2,978 shares in the last quarter. Intact Investment Management Inc. grew its stake in Zoetis by 475.0% in the 1st quarter. Intact Investment Management Inc. now owns 2,300 shares of the company's stock worth $379,000 after acquiring an additional 1,900 shares in the last quarter. Flagship Harbor Advisors LLC grew its stake in Zoetis by 31.2% in the 1st quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock worth $1,217,000 after acquiring an additional 1,760 shares in the last quarter. TrueMark Investments LLC bought a new position in Zoetis in the 1st quarter worth about $228,000. Finally, Oppenheimer Asset Management Inc. grew its stake in Zoetis by 18.6% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 275,734 shares of the company's stock worth $45,400,000 after acquiring an additional 43,325 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Up 0.7%

NYSE:ZTS opened at $145.11 on Tuesday. Zoetis Inc. has a 52 week low of $139.34 and a 52 week high of $193.00. The firm has a 50 day moving average of $148.65 and a 200 day moving average of $153.60. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The stock has a market capitalization of $64.31 billion, a price-to-earnings ratio of 24.98, a PEG ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. During the same quarter in the prior year, the company posted $1.56 earnings per share. Zoetis's revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. Zoetis's dividend payout ratio is presently 34.42%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on ZTS shares. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. UBS Group lowered their price target on shares of Zoetis from $165.00 to $158.00 and set a "neutral" rating for the company in a research report on Monday. Argus reaffirmed a "buy" rating and issued a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Finally, Piper Sandler upped their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Four investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, Zoetis presently has an average rating of "Hold" and an average price target of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.